

## Catalog # 10-1220 Anagrelide HCI

CAS# 58579-51-4 6,7-dichloro-1,5-dihydroimidazo[2,1 –b]quinazolin-2(3H)-one hydrochloride BL-4162A Lot # X108763



Potent and selective phosphodiesterase (PDE3) inhibitor,  $IC_{50}=36 \text{ nM}$ ).<sup>1</sup> Inhibits platelet production by disrupting megakaryocyte maturation<sup>2</sup> via a mechanism which is independent of PDE3 inhibition<sup>3</sup>. Clinically useful agent for conditions requiring platelet lowering therapy.<sup>4,5</sup>

- 1) Gilespie et al. (1988), Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity; Biochem. Pharmacol. **37** 2866
- Mazur et al. (1992), Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans; Blood, 79 1931
- 3) Wang et al. (2005), Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures; Br. J. Pharmacol., **146** 324
- 4) Barbui et al. (2012), Front-line therapy in polycythemia vera and essential thrombocythemia; Blood Rev., 26 205
- 5) Chen et al. (2012), Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis; Jpn. J. Clin. Oncol., **42** 761

## PHYSICAL DATA

Molecular Weight:	292.55
Molecular Formula:	C10H7Cl2N3O·HCl
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 2.5 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in
	DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.